Cargando…
Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis – Author’s reply
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7938745/ https://www.ncbi.nlm.nih.gov/pubmed/33705848 http://dx.doi.org/10.1016/j.cmi.2021.02.024 |
_version_ | 1783661646950957056 |
---|---|
author | Kashour, Tarek Tleyjeh, Imad M. |
author_facet | Kashour, Tarek Tleyjeh, Imad M. |
author_sort | Kashour, Tarek |
collection | PubMed |
description | |
format | Online Article Text |
id | pubmed-7938745 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-79387452021-03-09 Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis – Author’s reply Kashour, Tarek Tleyjeh, Imad M. Clin Microbiol Infect Letter to the Editor European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. 2021-08 2021-03-08 /pmc/articles/PMC7938745/ /pubmed/33705848 http://dx.doi.org/10.1016/j.cmi.2021.02.024 Text en © 2021 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Letter to the Editor Kashour, Tarek Tleyjeh, Imad M. Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis – Author’s reply |
title | Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis – Author’s reply |
title_full | Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis – Author’s reply |
title_fullStr | Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis – Author’s reply |
title_full_unstemmed | Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis – Author’s reply |
title_short | Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis – Author’s reply |
title_sort | efficacy and safety of tocilizumab in covid-19 patients: a living systematic review and meta-analysis – author’s reply |
topic | Letter to the Editor |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7938745/ https://www.ncbi.nlm.nih.gov/pubmed/33705848 http://dx.doi.org/10.1016/j.cmi.2021.02.024 |
work_keys_str_mv | AT kashourtarek efficacyandsafetyoftocilizumabincovid19patientsalivingsystematicreviewandmetaanalysisauthorsreply AT tleyjehimadm efficacyandsafetyoftocilizumabincovid19patientsalivingsystematicreviewandmetaanalysisauthorsreply |